<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04689425</url>
  </required_header>
  <id_info>
    <org_study_id>Long2020-DFU-MNC</org_study_id>
    <nct_id>NCT04689425</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer</brief_title>
  <acronym>DFU-MNC</acronym>
  <official_title>The Efficacy and Safety of Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Umbilical cord blood mononuclear cells (MNC) may improve the wound repair ability. This study&#xD;
      aims to investigate the role of MNC in refractory diabetic foot ulcer by comparing the&#xD;
      combination of PRP and MNC with PRP alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The difficulty in the healing of diabetic foot is related to the loss of local repair&#xD;
      microenvironment. The platelet rich plasma (PRP) can improve the repair ability, however, the&#xD;
      requirement for wound bed preparation is strict, or treatment failure may occur. Umbilical&#xD;
      cord blood mononuclear cells (MNC) may provide a better repair environment through paracrine&#xD;
      action. This study aims to investigate the role of MNC in refractory diabetic foot ulcer by&#xD;
      comparing the combination of PRP and MNC with PRP alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound area reduction rate</measure>
    <time_frame>one week</time_frame>
    <description>The ratio of the reduced area after one week of treatment to the original area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing rate at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of patients with healed wound at 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of patients with major amputation at 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>MNC+PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of PRP and MNC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PRP alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Umbilical cord blood mononuclear cell gel（MNC）</intervention_name>
    <description>Local wound treatment by combination of PRP and MNC, once;</description>
    <arm_group_label>MNC+PRP</arm_group_label>
    <other_name>MNC+PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The platelet rich plasma（PRP）</intervention_name>
    <description>Local wound treatment by PRP alone, once.</description>
    <arm_group_label>MNC+PRP</arm_group_label>
    <arm_group_label>PRP</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The age of the patients is 18-80 years old;&#xD;
&#xD;
          2. Diabetic foot is diagnosed and Wagner grade is above Ⅱ;&#xD;
&#xD;
          3. The duration of ulcer is 2 months or more, with no healing trend for 2 weeks or more.&#xD;
&#xD;
          4. Fasting blood glucose ≤ 9mmol / L, 2 hours postprandial blood glucose ≤ 13mmol / L;&#xD;
&#xD;
          5. The skin oxygen partial pressure around the wound is more than 20mmHg;&#xD;
&#xD;
          6. Sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute spreading infection of the wound, e.g. massive exudation, redness, swelling,&#xD;
             heat, pain.&#xD;
&#xD;
          2. Acute myocardial infarction, heart failure, hepatitis;&#xD;
&#xD;
          3. Active bleeding or hematoma in the wound;&#xD;
&#xD;
          4. Serum albumin &lt;25g/L;&#xD;
&#xD;
          5. Hemoglobin &lt;80g/L;&#xD;
&#xD;
          6. Platelets &lt;50×109/L;&#xD;
&#xD;
          7. Poor cooperate or compliance;The patient cannot cooperate or is.&#xD;
&#xD;
          8. Mentally disabled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Long Zhang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital Wound Healing Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Long Zhang, Dr.</last_name>
    <phone>+8613041210677</phone>
    <email>longzh2000@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen-Hui Wang, Dr.</last_name>
    <phone>+8618618269437</phone>
    <email>wwh0608@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>long zhang, Dr.</last_name>
      <phone>13041210677</phone>
      <email>longzh2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Long Zhang</investigator_full_name>
    <investigator_title>Chief Surgeon</investigator_title>
  </responsible_party>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>Umbilical cord blood mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication, for 1 year</ipd_time_frame>
    <ipd_access_criteria>The IPD and supporting information will be shared by contact PI (Long Zhang)'s Email, upon the request of the scientific journal editor.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

